Nuvation Bio Inc. Payments of Financing Costs
Nuvation Bio Inc. (NUVB) reported Payments of Financing Costs of $58.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-08-06
- Nuvation Bio Inc. payments of financing costs for the quarter ending 2026-06-30 was $58.69M, a 35253.61% increase year-over-year.
- Nuvation Bio Inc. payments of financing costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Nuvation Bio Inc. payments of financing costs for the quarter ending 2025-12-31 was $11.20M, a 46.72% increase year-over-year.
- Nuvation Bio Inc. payments of financing costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Nuvation Bio Inc. payments of financing costs for fiscal 2025 was $11.90M, a 30.67% decline from fiscal 2024.
- Nuvation Bio Inc. payments of financing costs for fiscal 2024 was $17.16M.
- Nuvation Bio Inc. payments of financing costs for fiscal 2023 was $0.00.
| Period end | Payments of Financing Costs 2 month | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $58.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $58.69M 10-Q · filed 2026-08-06 | $69.89M derived: sum of 3 quarters · filed 2026-08-06 | $69.89M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-04 | $11.20M derived: sum of 2 quarters · filed 2026-05-04 | $11.20M derived: sum of 3 quarters · filed 2026-05-04 | $11.37M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $11.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $11.20M derived: sum of 2 quarters · filed 2026-03-02 | $11.37M derived: sum of 3 quarters · filed 2026-08-06 | $11.90M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $166.00K derived: sum of 2 quarters · filed 2026-08-06 | $700.00K 10-Q · filed 2025-11-03 | $8.33M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $700.00K 10-Q · filed 2026-08-06 | $8.33M derived: sum of 3 quarters · filed 2026-08-06 | $11.54M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $534.00K 10-Q · filed 2026-05-04 | $8.17M derived: sum of 2 quarters · filed 2026-05-04 | $11.38M derived: sum of 3 quarters · filed 2026-05-04 | $17.70M derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | $7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $10.84M derived: sum of 2 quarters · filed 2026-03-02 | $17.16M derived: sum of 3 quarters · filed 2026-03-02 | $17.16M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $9.53M derived: sum of 2 quarters · filed 2025-11-03 | $9.53M 10-Q · filed 2025-11-03 | $9.53M derived: sum of 4 quarters · filed 2025-11-03 | |
| 2024-06-30 | $6.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $6.32M 10-Q · filed 2025-08-07 | $6.32M derived: sum of 3 quarters · filed 2025-08-07 | $6.32M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-05-07 | $0.00 derived: sum of 3 quarters · filed 2025-05-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-05 | ||||
| 2020-06-30 | $76.62K 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |